29 July 2016: India’s leading animal healthcare company, Hester Biosciences Limited has reported the following Q1 FY17 results:
Financial Highlights
Q1 FY17
|
Q1 FY16
|
Growth
|
FY16
| |
Net Sales (in INR cr)
|
30.13
|
24.53
|
23%
|
100.89
|
Net Profit (in INR cr)
|
5.99
|
4.66
|
29%
|
19.22
|
EPS in INR
|
7.05
|
5.48
|
29%
|
22.60
|
Q1 FY 17 Highlights:
· Hester has reported a Net Sales of INR 30.13 crore in Q1FY17 as compared to INR 24.53 crore for the previous corresponding period, thereby registering a growth of 23%.
· Net Profit for Q1 FY17 is recorded at INR 5.99 crore as against INR 4.66 crore for the previous corresponding period, thereby registering a growth of 29%.
· Earnings Per Share for the Q1FY17 are at INR 7.05 as against INR 5.48 for Q1FY16.
· Net Profit margin for Q1FY17 is 19.91% of sales as against 19.01% in Q1 FY 16
Business Overview
· The growth drivers continue to be inventory management, credit controls and product mix.
· The installation of a solar power generation project for 100KW has contributed towards reduction in energy costs up to INR 3 lakh in the first quarter.
· The sales in the poultry divisions grew by 19% while the large animal divisions have shown a growth of 41%.
· The company got the manufacturing license for 3 poultry vaccines during the quarter; with this company’s product portfolio has grown to 49 vaccines and 35 health products.
· Domestic sales grew by 21% while exports grew by 14%
About: Hester Biosciences Limited (www.hesterbiosciences.co.in)
Hester Biosciences Limited is one of India’s leading animal health care companies. Being the country’s second largest poultry vaccine manufacturer, Hester has rightly positioned itself to capitalise on upcoming opportunities in the animal health care industry globally.
Apart from poultry vaccines, the company has recently forayed into large animal vaccines, poultry health products and large animal health products. The four verticals put together will underpin Hester’s identity as a strong animal health company, addressing all segments in the animal health care sector.
Founded in 1987 by Mr. Rajiv Gandhi, a first generation entrepreneur, he converted a proprietary trading business into Asia’s largest single-location animal biological manufacturing facility. Benchmarked to international quality compliance standards, Hester manufactures and markets veterinary vaccines and health products in the Indian as well as the global markets.
The Company has a state-of-the-art manufacturing facility unit in Mehsana, Gujarat, complying with stringent international norms. Hester is WHO-GMP, Good Laboratory Practices (GLP), ISO 9001, ISO 14001 & OHSAS 18001 certified.
The Company’s product portfolio comprises of over 50 vaccines and over 35 health products, which are distributed through Hester’s pan-India distribution network. Exports are currently to 9 countries with registration process on in over 20 countries.
Hester’s key strength is embedded in its cutting-edge research and development capabilities. The Company’s R&D center is recognised by the Department of Scientific and Industrial Research (DSIR), Ministry of Science and Technology, Government of India.
A team of 300 motivated individuals drives Hester.
The company is listed on BSE and NSE. For the financial year 2015-16, it reported revenue of INR 100.89 crores with a net profit of INR 19.22 crores.